Compound Evidence File
#EC-2026-0797
Test Enanthate
Filed under Injectable Oils. The bureau holds 156 laboratory returns for this compound from 60 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
60 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 10.0 | 10.0 | 24 May 2026 | 14 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 5 Mar 2026 | 18 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 10.0 | 10.0 | 17 Jan 2026 | 22 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 10.0 | 10.0 | 7 Dec 2025 | 10 Aug 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Jan 2026 | 20 Mar 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 9.9 | 10.0 | 4 Mar 2026 | 1 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 10.0 | 10.0 | 10.0 | 20 Jan 2026 | 17 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 10.0 | 10.0 | 10.0 | 2 May 2026 | 3 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 10.0 | 10.0 | 10.0 | 17 Jan 2026 | 28 Jan 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 10.0 | 10.0 | 10.0 | 7 Dec 2025 | 23 Mar 2026 |
| NUPEPS PeptidesCASE #VI-2026-0896 | X | 1 | 10.0 | 10.0 | 10.0 | 9 Jun 2025 | 9 Jun 2025 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 9.9 | 9.9 | 10.0 | 19 Dec 2025 | 10 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 27 May 2026 | 4 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 8 Feb 2026 | 8 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 22 Mar 2026 | 1 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 18 Jan 2026 | 6 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 9.9 | 9.9 | 9.9 | 20 Dec 2025 | 28 Mar 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 5 Apr 2026 | 11 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 23 Mar 2026 | 20 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 27 Mar 2026 | 18 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 9.9 | 9 Jan 2026 | 19 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 18 Jul 2026 | 19 Jul 2026 |
| Risynth BioCASE #VI-2026-0672 | X | 1 | 9.6 | 9.6 | 9.6 | 27 Feb 2025 | 27 Feb 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.9 | 8.3 | 9.8 | 21 May 2026 | 21 May 2026 |
| Bfflist AMOCASE #VI-2026-0678 | X | 2 | 8.9 | 7.9 | 10.0 | 25 Apr 2025 | 17 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 2 | 8.8 | 8.5 | 9.0 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.7 | 7.1 | 10.0 | 25 May 2026 | 25 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 8.6 | 8.2 | 9.0 | 24 May 2026 | 24 May 2026 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 8.3 | 8.3 | 8.3 | 11 Jun 2025 | 11 Jun 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 7.9 | 7.6 | 8.2 | 21 May 2026 | 21 May 2026 |
| Quenna PMQCASE #VI-2026-0415 | X | 1 | 7.9 | 7.9 | 7.9 | 2 Apr 2025 | 2 Apr 2025 |
| Orbitrex PeptidesCASE #VI-2026-0812 | X | 1 | 7.8 | 7.8 | 7.8 | 7 May 2025 | 7 May 2025 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 7.7 | 7.7 | 7.7 | 13 Jun 2025 | 13 Jun 2025 |
| Simple PeptideCASE #VI-2026-0782 | X | 2 | 7.5 | 6.8 | 8.2 | 27 Feb 2025 | 21 May 2026 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 7.3 | 7.3 | 7.3 | 14 Jan 2025 | 14 Jan 2025 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 9 | 7.1 | 5.6 | 8.3 | 7 May 2025 | 21 May 2026 |
| Peptide SciencesCASE #VI-2026-0867 | X | 10 | 7.0 | 4.6 | 10.0 | 13 Feb 2025 | 24 May 2026 |
| PurePeptidesCASE #VI-2026-0234 | X | 1 | 7.0 | 7.0 | 7.0 | 13 Feb 2025 | 13 Feb 2025 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 6.5 | 6.5 | 6.5 | 24 Apr 2025 | 24 Apr 2025 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 2 | 6.4 | 5.8 | 7.1 | 3 Jun 2025 | 21 May 2026 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 6.4 | 6.4 | 6.4 | 25 Apr 2025 | 25 Apr 2025 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 6.2 | 6.2 | 6.2 | 13 Feb 2025 | 13 Feb 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 1 | 5.8 | 5.8 | 5.8 | 25 Apr 2025 | 25 Apr 2025 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 5.8 | 5.8 | 5.8 | 9 Jun 2025 | 9 Jun 2025 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 5.6 | 5.6 | 5.6 | 2 Jul 2025 | 2 Jul 2025 |
| EHZ PeptidesCASE #VI-2026-0296 | C | 3 | 4.9 | 4.0 | 6.6 | 2 Apr 2025 | 24 May 2026 |
| Suaway Lab ResearchCASE #VI-2026-0488 | X | 2 | 4.8 | 4.5 | 5.1 | 3 Jul 2025 | 24 May 2026 |
| Pharma Grade PeptidesCASE #VI-2026-0208 | X | 1 | 4.6 | 4.6 | 4.6 | 9 Jun 2025 | 9 Jun 2025 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 4.4 | 4.4 | 4.4 | 8 Jul 2025 | 8 Jul 2025 |
| WllyBIOCASE #VI-2026-0470 | X | 1 | 4.3 | 4.3 | 4.3 | 2 Apr 2025 | 2 Apr 2025 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 3.7 | 3.7 | 3.7 | 2 Jul 2025 | 2 Jul 2025 |
| DeuschemCASE #VI-2026-0004 | X | 1 | 2.1 | 2.1 | 2.1 | 14 Jan 2025 | 14 Jan 2025 |
| Coffee and PeppersCASE #VI-2026-0274 | X | 1 | 1.2 | 1.2 | 1.2 | 2 Apr 2025 | 2 Apr 2025 |
| Marvel PeptideCASE #VI-2026-0507 | X | 1 | 0.4 | 0.4 | 0.4 | 2 Apr 2025 | 2 Apr 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.0 | 0.0 | 0.0 | 2 Apr 2025 | 2 Apr 2025 |
| HK Fat CatCASE #VI-2026-0376 | X | 1 | 0.0 | 0.0 | 0.0 | 9 Jun 2025 | 9 Jun 2025 |
| PRIVATECASE #VI-2026-0635 | X | 1 | 0.0 | 0.0 | 0.0 | 3 Jun 2025 | 3 Jun 2025 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 0.0 | 0.0 | 0.0 | 3 Jul 2025 | 3 Jul 2025 |
Open any subject to view the batch-level evidence for Test Enanthate alone.